119 related articles for article (PubMed ID: 28267250)
1. Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?
Polónia A; Eloy C; Pinto J; Braga AC; Oliveira G; Schmitt F
Histopathology; 2017 Aug; 71(2):247-257. PubMed ID: 28267250
[TBL] [Abstract][Full Text] [Related]
2. HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity.
Polónia A; Caramelo A
Mod Pathol; 2021 Aug; 34(8):1478-1486. PubMed ID: 33980971
[TBL] [Abstract][Full Text] [Related]
3. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.
Polónia A; Leitão D; Schmitt F
Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674
[TBL] [Abstract][Full Text] [Related]
4. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
[TBL] [Abstract][Full Text] [Related]
5. Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.
Polónia A; Oliveira G; Schmitt F
Virchows Arch; 2017 Nov; 471(5):589-598. PubMed ID: 28702778
[TBL] [Abstract][Full Text] [Related]
6. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
[TBL] [Abstract][Full Text] [Related]
7. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
8. Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.
Nishimura R; Okamoto N; Satou M; Kojima K; Tanaka S; Yamashita N
Breast Cancer; 2016 Nov; 23(6):917-921. PubMed ID: 26746842
[TBL] [Abstract][Full Text] [Related]
9. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
10. Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.
Bartlett JM; Campbell FM; Ibrahim M; Wencyk P; Ellis I; Kay E; Connolly Y; O'Grady A; Di Palma S; Starczynski J; Morgan JM; Jasani B; Miller K
Am J Clin Pathol; 2009 Oct; 132(4):514-20. PubMed ID: 19762528
[TBL] [Abstract][Full Text] [Related]
11. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
Curado M; Caramelo AS; Eloy C; Polónia A
Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
[TBL] [Abstract][Full Text] [Related]
12. Determination of HER2 gene amplification in breast cancer using dual-color silver enhanced in situ hybridization (dc- SISH) and comparison with fluorescence ISH (FISH).
Unal B; Karaveli FS; Pestereli HE; Erdogan G
Asian Pac J Cancer Prev; 2013; 14(10):6131-4. PubMed ID: 24289638
[TBL] [Abstract][Full Text] [Related]
13. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
Casterá C; Bernet L
Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
[TBL] [Abstract][Full Text] [Related]
14. "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation.
Casterá Redal C; Bernet Vegué L
Ann Diagn Pathol; 2020 Oct; 48():151566. PubMed ID: 32763505
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HER2 status determination methods in HER2 (2+) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH).
Pehlivanoglu B; Serin G; Yeniay L; Zekioglu O; Gokmen E; Ozdemir N
Ann Diagn Pathol; 2017 Dec; 31():36-40. PubMed ID: 29146056
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong.
Tang SM; Soong IS; Luk MY; Suen DT; Hioe F; Man EP; Tsun OK; Khoo US
Hong Kong Med J; 2016 Apr; 22(2):144-51. PubMed ID: 26823385
[TBL] [Abstract][Full Text] [Related]
17. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
18. Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?
Prendeville S; Corrigan MA; Livingstone V; Feeley L; Bennett MW; Browne TJ; O'Connell F
Am J Clin Pathol; 2016 Mar; 145(3):316-22. PubMed ID: 27124913
[TBL] [Abstract][Full Text] [Related]
19. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer.
Koh YW; Lee HJ; Lee JW; Kang J; Gong G
Mod Pathol; 2011 Jun; 24(6):794-800. PubMed ID: 21317877
[TBL] [Abstract][Full Text] [Related]
20. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
